Every 10-Q that VolitionRx Limited (VNRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNRX filings page.
VolitionRx Limited reports very limited cash and continuing heavy losses in its quarter ended June 30, 2026. Cash and cash equivalents were $2.8 million, while net cash used in operating activities for the first six months was $10.4 million, resulting in a $14.0 million net loss on $1.4 million in revenue.
Total liabilities were $41.8 million against total assets of $8.3 million, leaving a stockholders’ deficit of $33.5 million and an accumulated deficit of $267.4 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes ongoing reliance on equity raises, convertible debt and grants.
The company is also working under a NYSE American compliance plan after receiving notice that its stockholders’ equity fell below the $6.0 million listing standard; it has until August 6, 2027 to regain compliance. VolitionRx continues to fund operations via offerings, an at-the-market program, and convertible notes with associated derivative and warrant liabilities.
VolitionRx Limited reported Q1 2026 revenues of $985,076, mainly from product sales, and a net loss of $6.7 million, or $0.97 per share. Operating cash outflow was $5.3 million, leaving cash and cash equivalents of $3.1 million and a stockholders’ deficit of $33.4 million as of March 31, 2026.
Management notes substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative cash flows and significant current liabilities, including convertible notes. The company is relying on equity raises, an at-the-market program and Lind convertible notes to fund ongoing development and commercialization of its Nu.Q and Capture-branded diagnostic tests.
VolitionRx Limited reported Q3 2025 results showing continued losses and tight liquidity. Revenue was $627,277, with an operating loss of $5,100,990 and a net loss of $5,409,791 for the quarter. For the nine months, revenue reached $1,280,350 and net loss totaled $17,200,488.
Cash and cash equivalents were $199,407 as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern. Total liabilities were $42,398,447 and stockholders’ deficit was $35,949,562 as of quarter-end.
VolitionRx raised capital through several transactions in 2025, including net proceeds of approximately $2.3 million in March and $1.21 million in August registered direct offerings, a $0.3 million private placement in September, and about $880,862 via its 2025 ATM Sales Agreement. The company also issued a $7.5 million senior secured convertible note, receiving net proceeds of $5,774,202, and later increased its ATM capacity from $7.5 million to $30.0 million. Shares outstanding were 122,801,572 as of November 7, 2025.
VolitionRx Limited filed Amendment No. 1 to its Quarterly Report for the period ended June 30, 2025. The amendment is described as a technical update filed solely to add missing exhibits that were inadvertently omitted from the original filing. Newly included are Exhibit 5.1, a legal opinion from Stradling Yocca Carlson & Rauth LLP, and Exhibit 10.2, Amendment No. 1 to the Capital On DemandTM Sales Agreement with JonesTrading Institutional Services LLC. The company also provides updated Section 302 Sarbanes-Oxley CEO and CFO certifications (Exhibits 31.3 and 31.4). The company states that no financial statements or other disclosures from the original report have been changed, and the amendment does not update the company’s financial position or results. As of August 7, 2025, 107,595,421 shares of common stock were issued and outstanding.
VolitionRX Limited (VNRX) reports a quarter marked by multiple equity financings and ongoing operational risks. The company raised net proceeds of approximately $6.4M from an August 2024 equity offering, $2.3M in March 2025 shares and warrants, $1.9M in December 2024 warrants and shares, and $5.8M net from the Lind offering, plus roughly $161,075 from ATM sales through June 30, 2025. Several warrant and pre-funded warrant issuances create potential dilution, with 58,234,651 potential common share equivalents excluded from diluted EPS as anti-dilutive. The filing discloses a going concern auditor opinion and identified material weaknesses in internal control over financial reporting. Product lines cited include Nu.Q Vet, Nu.Q NETs, Nu.Q Discover and Capture-PCR™ alongside ongoing efforts to centralize accounting and strengthen controls.